Mark R. Busch

Represented Exact Sciences Corporation (NASDAQ: EXAS), a biotechnology company headquartered in Wisconsin, in connection with issuance of US$500 million aggregate principal amount of a new series of 2.00% Convertible Senior Notes due 2030 in exchange for (i) US$183.7 million aggregate principal amount of existing 2027 Notes, (ii) US$200.9 million aggregate principal amount of existing 2028 Notes, and (iii) approximately US$138 million in cash.

Represented Movano Inc. (NASDAQ: MOVE), a purpose-driven health care solutions company at the intersection of medical and consumer devices and maker of the Evie Ring, with respect to an underwritten public offering of common stock with The Benchmark Company, LLC, a full-service investment banking firm, as the underwriter.

Represented Movano Inc. (NASDAQ: MOVE), a purpose-driven health care solutions company at the intersection of medical and consumer devices and maker of the Evie Ring, in connection with a $7.5 million underwritten public offering of common stock and warrants to purchase shares of common stock.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a biotechnology company headquartered in Wisconsin, in connection with issuance of US$72.9 million aggregate principal amount of a new series of 2.00% Convertible Senior Notes due 2030 in exchange for US$65.8 million aggregate principal amount of existing 2025 Notes.

Represented MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision-diagnostics company, in connection with a $40 million registered public offering of American Depositary Shares.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a biotechnology company headquartered in Wisconsin, in acquiring all of the outstanding equity interests of PreventionGenetics, a Wisconsin-based genetic testing laboratory. The combination complemented Exact Sciences' advanced cancer diagnostics portfolio and supports its entrance into hereditary cancer testing.

Served as U.S. counsel for MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, in its initial public offering of American Depositary Shares on the Nasdaq Capital Market. Piper Sandler and Oppenheimer & Co. Inc. served as lead underwriter in the offering, which raised US$45 million of proceeds for the company.

Advised Michigan-based ENDRA Life Sciences Inc. (NASDAQ: NDRA), a Nasdaq-listed medical device company developing thermoacoustic ultrasound technology, in establishing an at-the-market equity offering program with Ascendiant Capital Markets, LLC as sales agent. ENDRA may sell up to US$20.0 million of its common stock from time to time under the offering program. Ascendiant Capital Markets is a full-service boutique investment banking firm headquartered in California.

Represented Movano Inc. (NASDAQ: MOVE), a health technology company, in connection with its initial public offering of shares of common stock.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a molecular diagnostics company in connection with a number of underwritten public offerings of common stock and convertible notes with total gross proceeds exceeding $3 billion and a number of acquisitions with aggregate purchase prices exceeding $3 billion.

Represented a manufacturer of healthcare products with respect to a number of acquisitions.

Represented Energous Corporation (NASDAQ: WATT), a developer of wireless charging technology, in connection with its initial public offering and listing on NASDAQ and several follow-on secondary financing transactions.

Represented FlexShopper Inc. (NASDAQ: FPAY), an online lease-to-own retailer, in connection with PIPE transaction, NASDAQ uplisting and follow-on underwritten public offering.

Represented EnSync, Inc. (NYSE American: ESNC), an alternative energy company, in connection with several public and private offerings of shares of common stock, convertible preferred stock, warrants and convertible notes.

Represented Cue Biopharma, Inc. (NASDAQ: CUE), an immunotherapy company, in connection with its initial public offering and listing on NASDAQ and several follow-on at-the-market financing transactions.

Represented ENDRA Life Sciences Inc. (NASDAQ NDRA), an ultrasound technology company, in connection with its initial public offering and listing on NASDAQ and multiple follow-on offerings including bridge note financings, underwritten public offerings and at-the-market financing transactions.